Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.
Introduction
Regorafenib as a second-line therapy has been shown to improve overall survival in hepatocellular carcinoma (HCC) patients who show progression under sorafenib treatment (1) . However, the use of regorafenib is only recommended for patients who have tolerated sorafenib. We herein present the case of a patient in whom regorafenib could be continued for 10 months without severe adverse events after the discontinuation of sorafenib due to hypersensitivity.
Case Report
The patient was a 58-year-old man who was taken to a local hospital with acute abdominal pain in July 2011. Contrast-enhanced computed tomography (CT) revealed a ruptured tumor of 33 mm in diameter in hepatic segment 2. Hepatectomy was performed and a pathological examination of the resected specimen revealed moderately differentiated HCC without vascular invasion. The surrounding tissue was cirrhotic, which was considered to be the result of chronic alcohol abuse. Tests for hepatitis B surface antigens, hepatitis C antibodies and anti-nuclear antibodies were negative.
He had no comorbidities and was not receiving medication for any conditions other than liver disease. In 2015, radiofrequency ablation and transarterial chemoembolization (TACE) were performed to treat regional recurrence.
He was referred to our hospital for further management in January 2016. On presentation to our hospital, his Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 0 and his Barcelona Clinic Liver Cancer classification (BCLC) stage was C with multiple intrahepatic recurrences and peritoneal dissemination. Liver function tests revealed a Child-Pugh score of 5 (Table 1) . Sorafenib was started at a dose of 800 mg/day and was continued without symptoms. After 32 days, liver injury developed and sorafenib was discontinued. However, nausea and loss of appetite appeared, and the patient's liver injury showed progression. Intravenous methylprednisolone (1,000 mg) was administered for 3 days, followed by oral prednisolone until the patient made a full recovery from the liver injury. Prednisolone was slowly tapered over one month and was discontinued ( Fig. 1 ). At one month after the discontinuation of prednisolone, a drug-induced lymphocyte stimulation test (DLST) for sorafenib was negative. The stimulation index (SI) was 107%. The actual values of the test wells and control wells were 273 counts per minute (cpm) and 253 cpm, respec-Intern Med 58: 2803-2808, 2019 DOI: 10.2169/internalmedicine.2812-19 Figure 1 . The clinical course of the patient's alanine aminotransferase (ALT) and total bilirubin levels after sorafenib was initiated at a dose of 800 mg/day. After 32 days, liver injury develops. The ALT and total bilirubin levels were 874 U/L and 1.7 mg/dL, respectively. At two weeks after stopping sorafenib treatment the liver injury had worsened; the patient's ALT and total bilirubin levels were 1,665 U/L and 10.1 mg/dL, respectively. The patient was then given intravenous methylprednisolone (1,000 mg) for 3 days, followed by oral prednisolone until the patient made a full recovery from liver injury. Prednisolone was then slowly tapered over one month and discontinued. Contrast-enhanced CT during sorafenib treatment showed that most of the tumors changed from high-density to isodensity in the early arterial phase, and it was predicted that sorafenib would have an effect. In August 2016, sorafenib was restarted at a low dose of 200 mg/day with safety in mind. On the 5th day after restarting sorafenib, the patient developed a fever of >40 . The fever resolved quickly after the discontinuation of sorafenib. There was no skin disorder, eosinophilia, or liver injury. The DLST for sorafenib was re-peated, and the result was positive (SI: 380%; actual values: 650 cpm/171 cpm).
Treatment with uracil-tegafur, TACE for intrahepatic recurrence, and transcatheter arterial infusion for peritoneal metastasis were carried out. However, the response, according to the Response Evaluation Criteria in Solid Tumors, was progressive disease.
In June 2017, regorafenib was approved for the treatment of HCC in Japan. The approval was based on the results of the RESORCE trial, which used distinct criteria to include patients who tolerated sorafenib. Although the patient did not fulfill the criteria, he requested regorafenib treatment since no other systemic therapies were available. A multidisciplinary team was consulted, and it was thought that the absence of hypersensitivity to regorafenib should be confirmed before its administration. A DLST for regorafenib was performed, and the result was negative (SI: 155%; actual vales: 328 cpm/211 cpm). In September 2017, regorafenib was started at a reduced dose of 120 mg/day. The dosage was increased to 160 mg/day after 32 weeks. At the start of regorafenib therapy, he had an ECOG-PS score of 0 and BCLC stage C with portal vein invasion (Vp2). Liver function tests revealed a Child-Pugh score of 5 (Table 2) . Regorafenib was continued for 10 months during a long period of stable disease (SD). In July 2018, regorafenib was withdrawn after new vascular invasion and pulmonary metastasis were observed. The patient did not develop liver injury or fever and only showed mild side effects, such as hoarseness and grade 1 hand-foot skin reaction (Fig. 2) . Since a good performance status and liver function were maintained, with an ECOG-PS score of 0 and a Child-Pugh score of 6, regorafenib could be switched to lenvatinib. The patient continued to receive lenvatinib treatment at the time of writing this report (November 2018) (Fig. 3) .
The patient provided his written informed consent for the publication of the clinical details of the present case.
Discussion
This is the first report to show that regorafenib could be The expected 1-year survival of patients with advanced HCC with vascular invasion or extrahepatic spread is reported to be 30-50% in cases that follow a natural course (2, 3) . In the present case, the patient has survived for approximately three years since the peritoneal recurrence of HCC, as a result of multimodal treatment, including molecular targeted drugs and intra-arterial chemotherapy. This patient's long-term survival was attributed to regorafenib treatment, which was continued for 10 months in a long period of SD, despite the discontinuation of sorafenib due to severe adverse events, including liver injury and fever.
In treatment with tyrosine kinase inhibitors (TKIs), including sorafenib, serum aminotransferase elevation occurs in 20-50% of patients (4, 5) . The liver injury caused by sorafenib is mild in most cases and improves with the discontinuation of the drug (6, 7) . However, some fatal cases have been reported (8, 9) . Drug-induced liver injury (DILI) has been considered idiosyncratic (10) . The mechanisms underlying the development of idiosyncratic DILI can be broadly divided into hypersensitivity (i.e., immunologic) and metabolic mechanisms (11) . In the present case, a DLST for sorafenib was negative at one month after recovery from the liver injury. Thus, the patient's liver injury might have been associated with a metabolic mechanism and not hypersensitivity.
It has been reported that it is possible to restart sorafenib at a low dose after discontinuation due to severe adverse events, and that the dose can then be gradually increased to the usual therapeutic dose (12) . Some studies have reported that patients with either disappearance or a decrease in tumor enhancement on contrast-enhanced CT during sorafenib treatment showed a better prognosis than patients without these CT findings (13, 14) . In the present case, most tumors changed from high-density to iso-density during the first sorafenib treatment. Five days after restarting sorafenib at a dose of 200 mg/day, the patient developed a fever of >40 without liver injury. Considering the small dose and the short duration of treatment, the fever could be attributed to drug hypersensitivity. In fact, the DLST for sorafenib was positive at the time of the fever. The re-administration of sorafenib was abandoned due to the patient's drug hypersensitivity. The patient was probably sensitized to sorafenib during the first treatment and developed a fever due to hypersensitivity as a result of retreatment. Liver injury might have been avoided as a result of the early cessation and the small dose of sorafenib.
Regorafenib provided improved overall survival in HCC patients who showed progression during sorafenib treatment in the RESORCE trial (1) . Since the only subjects eligible for inclusion in this trial were patients who could tolerate sorafenib (! 400 mg daily for at least 20 of the 28 days before discontinuation), not all patients with PD after sorafenib treatment can be treated with regorafenib (15) . The present case did not meet this criterion. Nevertheless, regorafenib was administered for the following reasons. First, some reports have shown that the patients who developed severe liver injury with erlotinib or gefitinib, which are TKIs for lung cancer, successfully switched to the other agent without signs of recurrent liver injury. It is presumed that this is caused by the difference in the metabolic pharmacokinetics between the two TKIs, which share a 4-anilinoquinazoline base structure (16, 17) . In the present case there were some differences between the pharmacological activities of sorafenib and regorafenib, which have a very similar chemical structure (18, 19) . Second, in contrast to sorafenib, the DLST for regorafenib was negative. The DLST, also referred to as the lymphocyte transformation test, is used to identify the culprit drug in cases of adverse drug reactions. The test is a procedure that measures the proliferation of drug-specific T cells in vitro. The T cell receptor can interact directly with the drug itself. Additionally, the positive rate was approximately 78%, which is considered low (20) . Thus, attention must be paid to the interpretation of this result. In the present case, the patient had been hospitalized two weeks after the start of regorafenib at a reduced dose and was followed constantly. Third, there was no other therapeutic agent available at that time, and the patient therefore strongly desired regorafenib treatment.
In the present case, regorafenib treatment was continued safely for 10 months, despite sorafenib having been discontinued due to severe adverse events, such as DILI and drug hypersensitivity. Although sorafenib and regorafenib have similar structures, the survival benefit provided by the sequential use of regorafenib after progression on sorafenib suggests that they there are some differences in their mechanisms of action. Those differences are poorly understood and might account for the differences in side effects.
In conclusion, under multimodal treatment, including three molecular targeted drugs and intra-arterial chemotherapy, the present patient has survived for approximately 3 years since the peritoneal recurrence of HCC. The patient's long-term survival was attributed to the administration of regorafenib for 10 months during a long period of SD, despite the discontinuation of sorafenib due to severe adverse events (e.g., liver injury and fever). Physicians should exercise caution when switching therapy from sorafenib to regorafenib because the two drugs have a very similar chemical structure. This is the first report showing that regorafenib could be safely administered for advanced HCC after the discontinuation of sorafenib due to hypersensitivity.
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